user

The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

被引：0
|
作者：
Jin, Feng [1 ]
Robeson, Michelle [2 ]
Zhou, Huafeng [2 ]
Hisoire, Grace [1 ]
Ramanathan, Srini [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Gilead Sci Inc, Seattle, WA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT204
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    BLOOD, 2013, 122 (21)
  • [2] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    F. Jin
    M. Robeson
    H. Zhou
    G. Hisoire
    S. Ramanathan
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1133 - 1141
  • [3] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    Jin, F.
    Robeson, M.
    Zhou, H.
    Hisoire, G.
    Ramanathan, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1133 - 1141
  • [4] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (08): : 944 - 952
  • [5] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment<bold> </bold>
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    BLOOD, 2013, 122 (21)
  • [7] The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
    Magee, Mindy He
    Shaddinger, Bonnie
    Collins, David
    Siddiqi, Shabana
    Soffer, Joseph
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (04) : 654 - 661
  • [8] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S87 - S88
  • [9] PHARMACOKINETICS OF BRIVARACETAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT
    Stockis, A.
    Jacobs, T.
    Leonard, M.
    Sargentini-Maier, M. L.
    EPILEPSIA, 2010, 51 : 122 - 123
  • [10] Effect of Renal Impairment on the Pharmacokinetics and Safety of Rivipansel in Subjects with Renal Impairment and in Healthy Subjects
    Tammara, Brinda
    Ryan, Kelly
    Plotka, Anna
    Shafer, Frank E.
    Wei, Hua
    Readett, David
    Fang, Annie
    Korth-Bradley, Joan
    BLOOD, 2018, 132
12345